2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T5ab,Although human papillomavirus (HPV) vaccines effectively prevent cervical cancer, the HPV vaccination rates in Japan remain low because of concerns about alleged neurological adverse events. Darja Kanduc proposed a flawed hypothesis that molecular mimicry between HPV and human proteins could induce cross-reactive antibodies, causing autoimmune organ damage, even when only the portions of amino acid (AA)-sequences of the epitopes were identical between HPV and human proteins. In this study, we conducted the same computational data analysis as Kanduc, using 22 linear epitopes (9-23 AA-length) of the HPV type 16 L1 protein (HPV16L1) registered in the database. We found that no human epitopes had identical AA-sequences to any HPV16L1 epitopes, demonstrating that HPV16L1 had no molecular mimicry with linear epitopes that have the potential to induce cross-reactive autoantibodies. On the other hand, we identified various numbers of human protein epitopes whose AA-sequences were partially identical with epitopes of HPV16L1, hepatitis B virus (HBV), and respiratory syncytial virus (RSV). We found that HPV16L1 had a smaller number of such proteins having "partial molecular mimicry" than HBV and RSV. Our current in silico analysis provided no evidence that HPV vaccinations could induce cross-reactive autoantibodies. The flawed molecular mimicry data should not be used as a scientific basis for alleged HPV vaccine-induced adverse events.31:T82e,Abstract Background Although human papillomavirus (HPV) vaccines effectively prevent cervical cancer, the HPV vaccination rates in Japan remain low because of concerns about alleged neurological adverse events. Darja Kanduc proposed a flawed hypothesis that molecular mimicry between HPV and human proteins could induce cross-reactive antibodies, causing autoimmune organ damage, even when only the portions of amino acid (AA)-sequences of the epitopes were identical between HPV and human proteins. Methods In this study, we conducted the same computational data analysis as Kanduc, using 22 linear epitopes (9–23 AA-length) of the HPV type 16 L1 protein (HPV16L1) registered in the database. Results We found that no human epitopes had identical AA-sequences to any HPV16L1 epitopes, demonstrating that HPV16L1 had no molecular mimicry with linear epitopes that have the potential to induce cross-reactive autoantibodies. On the other hand, we identified various numbers of human protein epitopes whose AA-sequences were partially identical with epitopes of HPV16L1, hepatitis B virus (HBV), and respiratory syncytial virus (RSV). We found that HPV16L1 had a smaller number of such proteins having “partial molecular mimicry” than HBV and RSV. Conclusions Our current in silico analysis provided no evidence that HPV vaccinations could induce cross-reactive autoantibodies. The flawed molecular mimicry data should not be used as a scientific basis for alleged HPV vaccine-induced adverse events. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"In Silico Analysis: study design Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on In Silico Analysis (study design). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/study_design/In%20Silico%20Analysis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study Designs\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"In Silico Analysis\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design/In%20Silico%20Analysis\"}]}}"}}]],["$","$L2f",null,{"title":"In Silico Analysis: Research & Clinical Takeaways","description":"Browse In Silico Analysis research papers with clear, practical takeaways for your clinical practice.","papers":[{"doi":"10.1007/s10147-026-02961-z","pmid":"41507632","title":"Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis","journal_title":"International Journal of Clinical Oncology","journal_issn":"1341-9625","published_at":"2026-01-09T00:00:00.000Z","url":"https://doi.org/10.1007/s10147-026-02961-z","source_score":177,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-09","doi":"10.1007/s10147-026-02961-z","days":"14","issn":"1341-9625","rank":"5","field":"Clinical Medicine","score":"177","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1007/s10147-026-02961-z","title":"Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis.","journal":"International journal of clinical oncology","methods":"","results":"We found that no human epitopes had identical AA-sequences to any HPV16L1 epitopes, demonstrating that HPV16L1 had no molecular mimicry with linear epitopes that have the potential to induce cross-reactive autoantibodies. On the other hand, we identified various numbers of human protein epitopes whose AA-sequences were partially identical with epitopes of HPV16L1, hepatitis B virus (HBV), and respiratory syncytial virus (RSV). We found that HPV16L1 had a smaller number of such proteins having \"partial molecular mimicry\" than HBV and RSV.","abstract":"$30","keywords":["Amino Acid Sequences","Autoimmunity","Cross Reactions","HANS","Uterine Cervical Neoplasms"],"pubmed_id":"41507632","conclusions":"","publication_date":"2026-01-09T00:00:00"},"crossref":{"DOI":"10.1007/s10147-026-02961-z","URL":"https://doi.org/10.1007/s10147-026-02961-z","ISSN":["1341-9625","1437-7772"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s10147-026-02961-z.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s10147-026-02961-z","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s10147-026-02961-z.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis"],"author":[{"given":"Kazuhiro","family":"Nishioka","sequence":"first","affiliation":[]},{"given":"Kentaro","family":"Sekiyama","sequence":"additional","affiliation":[]},{"given":"Reona","family":"Shiro","sequence":"additional","affiliation":[]},{"given":"Ikuo","family":"Tsunoda","sequence":"additional","affiliation":[]},{"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100001691","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001691","name":"Japan Society for the Promotion of Science","award":["JP23K08901"],"award-info":[{"award-number":["JP23K08901"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001691","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001691","name":"Japan Society for the Promotion of Science","award":["JP22K18378/JP23K08901/JP24K10163"],"award-info":[{"award-number":["JP22K18378/JP23K08901/JP24K10163"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100012043","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100012043","name":"Kindai University","award":["KD2506"],"award-info":[{"award-number":["KD2506"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,8]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2026-01-08T18:57:38Z","timestamp":1767898658000,"date-parts":[[2026,1,8]]},"indexed":{"date-time":"2026-01-09T00:34:41Z","timestamp":1767918881997,"date-parts":[[2026,1,9]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000,"date-parts":[[2026,1,8]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000,"date-parts":[[2026,1,8]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s10147-026-02961-z"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"13 September 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"3 January 2026"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"8 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"N.M. received lecture fees from AstraZeneca, Takeda Pharmaceutical, MSD, and Eisai, and research grants from AstraZeneca and Eisai. N.M. is an outside director of Takara Bio Inc. Other authors declare no conflicts of interest."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"},"order":3,"value":"Approval of the research protocol by an Institutional Reviewer Board: N/A."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"},"order":4,"value":"N/A"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the Registration No. of the study/trial"},"order":5,"value":"N/A"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal Studies"},"order":6,"value":"N/A"}],"deposited":{"date-time":"2026-01-08T18:57:39Z","timestamp":1767898659000,"date-parts":[[2026,1,8]]},"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"published":{"date-parts":[[2026,1,8]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1007/s10147-024-02473-8","key":"2961_CR1","year":"2024","issue":"4","author":"H Nakai","volume":"29","first-page":"363","unstructured":"Nakai H, Higashi T, Kakuwa T et al (2024) Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol 29(4):363–371. https://doi.org/10.1007/s10147-024-02473-8","article-title":null,"journal-title":"Int J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10147-023-02337-7","key":"2961_CR2","year":"2023","issue":"8","author":"M Kusakabe","volume":"28","first-page":"965","unstructured":"Kusakabe M, Taguchi A, Sone K et al (2023) Carcinogenesis and management of human papillomavirus-associated cervical cancer. Int J Clin Oncol 28(8):965–974. https://doi.org/10.1007/s10147-023-02337-7","article-title":null,"journal-title":"Int J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa061741","key":"2961_CR3","year":"2007","issue":"19","author":"The FUTURE II Study Group","volume":"356","first-page":"1915","unstructured":"The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927. https://doi.org/10.1056/NEJMoa061741","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(09)61248-4","key":"2961_CR4","year":"2009","issue":"9686","author":"J Paavonen","volume":"374","first-page":"301","unstructured":"Paavonen J, Naud P, Salmerón J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 374(9686):301–314. https://doi.org/10.1016/S0140-6736(09)61248-4","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1405044","key":"2961_CR5","year":"2015","issue":"8","author":"EA Joura","volume":"372","first-page":"711","unstructured":"Joura EA, Giuliano AR, Iversen OE et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711–723. https://doi.org/10.1056/NEJMoa1405044","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.vaccine.2017.05.069","key":"2961_CR6","year":"2017","issue":"43","author":"World Health Organization","volume":"35","first-page":"5753","unstructured":"World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine 35(43):5753–5755. https://doi.org/10.1016/j.vaccine.2017.05.069","article-title":null,"journal-title":"Vaccine","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2016.1267085","key":"2961_CR7","year":"2017","issue":"5","author":"Y Tanaka","volume":"13","first-page":"1167","unstructured":"Tanaka Y, Ueda Y, Kimura T (2017) Struggles within Japan’s national HPV vaccination: a proposal for future strategy. Hum Vaccin Immunother 13(5):1167–1168. https://doi.org/10.1080/21645515.2016.1267085","article-title":null,"journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pvr.2018.02.002","key":"2961_CR8","year":"2018","issue":null,"author":"S Suzuki","volume":"5","first-page":"96","unstructured":"Suzuki S, Hosono A (2018) No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res 5:96–103. https://doi.org/10.1016/j.pvr.2018.02.002","article-title":null,"journal-title":"Papillomavirus Res","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10147-023-02411-0","key":"2961_CR9","year":"2023","issue":"12","author":"S Nakagawa","volume":"28","first-page":"1667","unstructured":"Nakagawa S, Yagi A, Ueda Y et al (2023) Intentions for catch-up HPV vaccination in Japan: an internet survey. Int J Clin Oncol 28(12):1667–1679. https://doi.org/10.1007/s10147-023-02411-0","article-title":null,"journal-title":"Int J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1111/cas.15482","key":"2961_CR10","year":"2022","issue":"10","author":"N Matsumura","volume":"113","first-page":"3313","unstructured":"Matsumura N, Tsunoda I (2022) Scientific evaluation of alleged findings in HPV vaccines: molecular mimicry and mouse models of vaccine-induced disease. Cancer Sci 113(10):3313–3320. https://doi.org/10.1111/cas.15482","article-title":null,"journal-title":"Cancer Sci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2016.07.030","key":"2961_CR11","year":"2016","issue":"11","author":"D Kanduc","volume":"15","first-page":"1054","unstructured":"Kanduc D, Shoenfeld Y (2016) From HBV to HPV: designing vaccines for extensive and intensive vaccination campaigns worldwide. Autoimmun Rev 15(11):1054–1061. https://doi.org/10.1016/j.autrev.2016.07.030","article-title":null,"journal-title":"Autoimmun Rev","doi-asserted-by":"publisher"},{"DOI":"10.1038/cmi.2017.151","key":"2961_CR12","year":"2018","issue":null,"author":"Y Segal","volume":"15","first-page":"586","unstructured":"Segal Y, Shoenfeld Y (2018) Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 15:586–594. https://doi.org/10.1038/cmi.2017.151","article-title":null,"journal-title":"Cell Mol Immunol","doi-asserted-by":"publisher"},{"DOI":"10.2807/1560-7917.ES.2022.27.4.2001619","key":"2961_CR13","year":"2022","issue":"4","author":"TS Boender","volume":"27","first-page":null,"unstructured":"Boender TS, Bartmeyer B, Coole L et al (2022) Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 january 2000 to 4 april 2020. Euro Surveill 27(4):2001619. https://doi.org/10.2807/1560-7917.ES.2022.27.4.2001619","article-title":null,"journal-title":"Euro Surveill","doi-asserted-by":"publisher"},{"DOI":"10.4137/jeo.s2009.08","key":"2961_CR14","year":"2009","issue":"1","author":"D Kanduc","volume":"8","first-page":"65","unstructured":"Kanduc D (2009) Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 8(1):65–76. https://doi.org/10.4137/jeo.s2009.08","article-title":null,"journal-title":"J Exp Ther Oncol","doi-asserted-by":"publisher"},{"DOI":"10.5897/IJMMS.9000169","key":"2961_CR15","year":"2009","issue":"9","author":"D Kanduc","volume":"1","first-page":"383","unstructured":"Kanduc D (2009) Penta- and hexapeptide sharing between HPV16 and Homo sapiens proteomes. Int J Med Med Sci 1(9):383–387. https://doi.org/10.5897/IJMMS.9000169","article-title":null,"journal-title":"Int J Med Med Sci","doi-asserted-by":"publisher"},{"DOI":"10.1159/000502889","key":"2961_CR16","year":"2019","issue":"5–6","author":"D Kanduc","volume":"86","first-page":"285","unstructured":"Kanduc D, Shoenfeld Y (2019) Human papillomavirus epitope mimicry and autoimmunity: the molecular truth of peptide sharing. Pathobiology 86(5–6):285–295. https://doi.org/10.1159/000502889","article-title":null,"journal-title":"Pathobiology","doi-asserted-by":"publisher"},{"DOI":"10.1007/BF02256597","key":"2961_CR17","year":"2001","issue":"3","author":"MP Cooreman","volume":"8","first-page":"237","unstructured":"Cooreman MP, Leroux-Roels G, Paulij WP (2001) Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8(3):237–247. https://doi.org/10.1007/BF02256597","article-title":null,"journal-title":"J Biomed Sci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajt.2024.02.003","key":"2961_CR18","year":"2024","issue":"6","author":"P Trubin","volume":"24","first-page":"897","unstructured":"Trubin P, Azar MM, Kotton CN (2024) The respiratory syncytial virus vaccines are here: implications for solid organ transplantation. Am J Transplant 24(6):897–904. https://doi.org/10.1016/j.ajt.2024.02.003","article-title":null,"journal-title":"Am J Transplant","doi-asserted-by":"publisher"},{"DOI":null,"key":"2961_CR19","year":"2022","issue":null,"author":"C Seeger","volume":null,"first-page":"641","unstructured":"Seeger C, Zoulim F, Mason WS (2022) Hepadnaviridiae. In: Howley PM, Knipe DM (eds) Fields Virology Volume 2: DNA Viruses, 7th edn. Wolters Kuwer, Philadelphia, PA, pp 641–682","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2961_CR20","year":"2023","issue":null,"author":"UJ Buchhoz","volume":null,"first-page":"267","unstructured":"Buchhoz UJ, Anderson LJ, Collins PL et al (2023) Respiratory syncytial virus and metapneumovirus. In: Howley PM, Knipe DM (eds) Fields Virology Volume 3: RNA Viruses, 7th edn. Wolters Kuwer, Philadelphia, PA, pp 267–317","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/jama.2014.16946","key":"2961_CR21","year":"2015","issue":"1","author":"NM Scheller","volume":"313","first-page":"54","unstructured":"Scheller NM, Svanström H, Pasternak B et al (2015) Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 313(1):54–61. https://doi.org/10.1001/jama.2014.16946","article-title":null,"journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2017.1423155","key":"2961_CR22","year":"2018","issue":"5","author":"A Meggiolaro","volume":"14","first-page":"1266","unstructured":"Meggiolaro A, Migliara G, Torre GL (2018) Association between human papilloma virus (HPV) vaccination and risk of multiple sclerosis: a systematic review. Hum Vaccin Immunother 14(5):1266–1274. https://doi.org/10.1080/21645515.2017.1423155","article-title":null,"journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1111/cas.15714","key":"2961_CR23","year":"2023","issue":"4","author":"N Matsumura","volume":"114","first-page":"1218","unstructured":"Matsumura N, Shiro R, Tsunoda I (2023) Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine-induced adverse events. Cancer Sci 114(4):1218–1228. https://doi.org/10.1111/cas.15714","article-title":null,"journal-title":"Cancer Sci","doi-asserted-by":"publisher"},{"DOI":"10.1074/mcp.M115.051664","key":"2961_CR24","year":"2016","issue":"4","author":"M Hecker","volume":"15","first-page":"1360","unstructured":"Hecker M, Fitzner B, Wendt M et al (2016) High-density peptide microarray analysis of IgG autoantibody reactivities in serum and cerebrospinal fluid of multiple sclerosis patients. Mol Cell Proteomics 15(4):1360–1380. https://doi.org/10.1074/mcp.M115.051664","article-title":null,"journal-title":"Mol Cell Proteomics","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2022.1097871","key":"2961_CR25","year":"2023","issue":null,"author":"JC Prinz","volume":"13","first-page":null,"unstructured":"Prinz JC (2023) Immunogenic self-peptides - the great unknowns in autoimmunity: identifying T-cell epitopes driving the autoimmune response in autoimmune diseases. Front Immunol 13:1097871. https://doi.org/10.3389/fimmu.2022.1097871","article-title":null,"journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtauto.2025.100269","key":"2961_CR26","year":"2025","issue":null,"author":"M Fehringer","volume":"10","first-page":null,"unstructured":"Fehringer M, Vogl T (2025) Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases. J Transl Autoimmun 10:100269. https://doi.org/10.1016/j.jtauto.2025.100269","article-title":null,"journal-title":"J Transl Autoimmun","doi-asserted-by":"publisher"},{"DOI":"10.1038/s42003-021-01932-6","key":"2961_CR27","year":"2021","issue":null,"author":"S Megremis","volume":"4","first-page":"419","unstructured":"Megremis S, Walker TDJ, He X et al (2021) Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis. Commun Biol 4:419. https://doi.org/10.1038/s42003-021-01932-6","article-title":null,"journal-title":"Commun Biol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12026-020-09152-6","key":"2961_CR28","year":"2020","issue":null,"author":"D Kanduc","volume":"68","first-page":"310","unstructured":"Kanduc D, Shoenfeld Y (2020) Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res 68:310–313. https://doi.org/10.1007/s12026-020-09152-6","article-title":null,"journal-title":"Immunol Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2021.102792","key":"2961_CR29","year":"2021","issue":"4","author":"A Dotan","volume":"20","first-page":null,"unstructured":"Dotan A, Muller S, Kanduc D et al (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792. https://doi.org/10.1016/j.autrev.2021.102792","article-title":null,"journal-title":"Autoimmun Rev","doi-asserted-by":"publisher"},{"DOI":"10.3390/antib10040036","key":"2961_CR30","year":"2021","issue":"4","author":"D Kanduc","volume":"10","first-page":null,"unstructured":"Kanduc D (2021) From anti-SARS-CoV-2 immune response to the cytokine storm via molecular mimicry. Antibodies 10(4):36. https://doi.org/10.3390/antib10040036","article-title":null,"journal-title":"Antibodies","doi-asserted-by":"publisher"},{"DOI":"10.1055/s-0043-1768699","key":"2961_CR31","year":"2023","issue":"2","author":"D Kanduc","volume":"10","first-page":"072","unstructured":"Kanduc D (2023) Exposure to SARS-CoV-2 and infantile diseases. Glob Med Genet 10(2):072–078. https://doi.org/10.1055/s-0043-1768699","article-title":null,"journal-title":"Glob Med Genet","doi-asserted-by":"publisher"},{"DOI":"10.1055/s-0043-1776985","key":"2961_CR32","year":"2023","issue":"4","author":"D Kanduc","volume":"10","first-page":"311","unstructured":"Kanduc D (2023) Molecular mimicry between meningococcal B factor H-binding protein and human proteins. Glob Med Genet 10(4):311–314. https://doi.org/10.1055/s-0043-1776985","article-title":null,"journal-title":"Glob Med Genet","doi-asserted-by":"publisher"},{"DOI":"10.2217/imt.10.83","key":"2961_CR33","year":"2011","issue":"1","author":"SL Bavaro","volume":"3","first-page":"49","unstructured":"Bavaro SL, Kanduc D (2011) Pentapeptide commonality between Corynebacterium diphtheriae toxin and the Homo sapiens proteome. Immunotherapy 3(1):49–58. https://doi.org/10.2217/imt.10.83","article-title":null,"journal-title":"Immunotherapy","doi-asserted-by":"publisher"},{"DOI":"10.1055/s-0043-1761489","key":"2961_CR34","year":"2023","issue":"01","author":"D Kanduc","volume":"10","first-page":"19","unstructured":"Kanduc D (2023) Molecular mimicry between respiratory syncytial virus F antigen and the human proteome. Glob Med Genet 10(01):19–21. https://doi.org/10.1055/s-0043-1761489","article-title":null,"journal-title":"Glob Med Genet","doi-asserted-by":"publisher"},{"DOI":"10.2147/btt.s8890","key":"2961_CR35","year":"2010","issue":null,"author":"R Ricco","volume":"4","first-page":"75","unstructured":"Ricco R, Kanduc D (2010) Hepatitis B virus and Homo sapiens proteome-wide analysis: a profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 4:75–81. https://doi.org/10.2147/btt.s8890","article-title":null,"journal-title":"Biologics","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["2961"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["International Journal of Clinical Oncology"],"reference-count":35,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,8]]},"references-count":35,"short-container-title":["Int J Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s10147-026-02961-z","is_oa":true,"title":"Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis","updated":"2026-01-11T01:49:12+00:00","published_date":"2026-01-08","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s10147-026-02961-z.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s10147-026-02961-z.pdf","url_for_landing_page":"https://doi.org/10.1007/s10147-026-02961-z"}}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"condition","value":"Autoimmune Diseases","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"condition","value":"Human Papillomavirus Infection","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"modality","value":"Vaccine","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"study_design","value":"In Silico Analysis","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"warning","value":"Design is computational/in silico and does not map cleanly to standard clinical study categories.","value_numeric":null},{"paper_doi":"10.1007/s10147-026-02961-z","tag_type":"warning","value":"No patient population, comparator, or timeframe were reported.","value_numeric":null}],"summaries":{"what_studied":"An in silico BLAST comparison of 22 documented linear B‑cell epitopes (9–27 amino acids) from HPV16 L1 against human antibody epitope sequences, with parallel analyses using HBV and RSV epitopes and randomly generated sequences.","key_result":"No human epitopes were identical to any of the 22 HPV16 L1 epitopes. Partial identity occurred only at short lengths (human matches: 1281 pentapeptides, 106 hexapeptides, 16 heptapeptides, 2 octa- and 2 nonapeptides; none ≥10 AAs), and HPV16 L1 had fewer such matches than HBV and RSV.","limitations":"This is an in silico analysis restricted to linear epitope databases and cannot assess conformational epitopes or actual antibody binding. No functional or clinical validation was performed within this study.","practice_takeaway":"These computational data provide no evidence that HPV16 L1 epitopes generate cross‑reactive autoantibodies via molecular mimicry; short sequence overlaps alone should not be used to claim HPV vaccine–related autoimmune risk."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"study_design","value":"In Silico Analysis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study Designs","href":"/hub/tag/study_design"},{"name":"In Silico Analysis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"study_design","hub_tag_value":"In Silico Analysis"}}}]]

Papers